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Abstract: Environmental factors including chronic stress may play a critical role in the manifestation of Alzheimer’s  
disease (AD).This review summarizes our studies of the aggravation of the impaired cognitive ability and its cellular  
and molecular correlates by chronic psychosocial stress and prevention by nicotine in an A rat model of AD. We   
utilized three approaches: learning and memory tests in the radial arm water maze, electrophysiological recordings of  
the cellular correlates of memory, long-term potentiation (LTP) and long-term depression (LTD), in anesthetized rats, and 
immunoblot analysis of synaptic plasticity- and cognition-related signaling molecules. The A rat model, representing the 
sporadic form of established AD, was induced by continuous i.c.v. infusion of a pathogenic dose of A peptides via a 14-
day osmotic pump. In this AD model, chronic stress intensified cognitive deficits, accentuated the disruption of signaling 
molecules levels and produced greater depression of LTP than what was seen with A infusion alone. Chronic treatment 
with nicotine was highly efficient in preventing the effects of A infusion and the exacerbating impact of chronic stress. 
Possible mechanisms for the effect of chronic stress are discussed. 
Keywords: Rat AD model, amyloid-beta, learning and memory, signaling molecules, synaptic plasticity, chronic nicotine, 
chronic stress. 
1. INTRODUCTION 
  Alzheimer’s disease (AD) is an irreversible, progressive 
neurodegenerative brain disorder characterized by extra- 
cellular accumulation of pathogenic amyloid-beta (A) 
peptides, intracellular aggregation of hyperphosphorylated tau 
protein, and neuronal death [1, 2]. The early symptom of the 
disease is a slow and insidious destruction of memory and 
cognitive skills. Molecular studies have shown that missense 
mutations in genes for amyloid precursor protein (APP), 
presenilin 1 (PS1) or presenilin 2 (PS2) account for the 
majority of familial AD cases [3-5]. However the early-onset 
familial AD represents less than 5% of AD cases, while the 
sporadic, late-onset AD is evident in the vast majority of the 
cases [4, 5]. Because of the poor correlation of the severity of 
dementia with the extent of neuronal loss and degree of 
fibrillar A load in the AD brain, the original amyloid cascade 
hypothesis has been substantially revised. It is now thought 
that certain oligomeric forms of soluble A can cause 
cognitive impairment in animals in the absence of neuro- 
degeneration [6]. Additionally, synaptic plasticity, including 
long-term potentiation (LTP) and long-term depression 
(LTD), the cellular correlates of learning and memory, are 
highly vulnerable to disruption by soluble A species [7]. 
  The sporadic nature of this disorder suggests an environ- 
mental link that may trigger AD pathogenesis. In addition to 
its late-onset, the variation in susceptibility to and time of 
onset of the disease suggests that aside from genetic factors, 
environmental determinants, such as chronic stress, may   
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also play a critical role in the severity of sporadic form of 
AD. Additionally, during AD, a progressive failure of synaptic 
transmission occurs; it begins as a localized decrease in 
synaptic function, and over time, progresses to global 
impairment of neurotransmission in the brain [4, 7, 8]. 
  Chronic stress is a homeostatic challenge with physical 
and psychological ramifications and a particularly negative 
effect on the learning and memory process [9-14]. It is 
known that stress aggravates cognitive impairment in various 
disorders including schizophrenia [15], Cushing’s disease 
[16], hypothyroidism [17], and AD [18-21]. Based on 
clinical reports of elevated plasma cortisol levels in 
individuals with dementia and in AD patients [22-25], it has 
been postulated that stress may be associated with this 
disease [26-28]. Further support of this hypothesis comes 
from epidemiological findings that stressed individuals are 
more likely to develop mild cognitive impairment, or even 
AD, than non-stressed individuals [29, 30]. Clinical reports 
of hypercortism in AD patients [25, 31] and animal studies 
[32, 33] have shown that glucocorticoids participate in the 
regulation of APP levels suggesting involvement of these 
hormones in the pathogenesis of AD. Stress activates the 
hypothalamic-pituitary-adrenal (HPA) axis resulting in 
glucocorticoids blood levels high enough to activate type-II 
glucocorticoid receptors with negative consequences for 
hippocampal function [34-36]. Because of the abundance of 
glucocorticoid receptors in the hippocampus and its 
involvement in cognition, chronic stress can have deleterious 
effects on the hippocampal structure and function [37].  
  Most epidemiological studies have reported a highly   
significant negative correlation between cigarette smoking 
and AD [38-40, 42 but see 42, 43]. Laboratory and clinical 588    Current Neuropharmacology, 2011, Vol. 9, No. 4  Karim A. Alkadhi 
studies have shown that nicotine improves cognitive function 
in AD patients and attenuates A-induced amnesia in rodents 
[19, 40, 44, 45].The finding that chronic nicotine treatment 
prevents stress-induced down regulation of central nicotinic 
acetylcholine receptors (nAChRs) [46], suggests a mechanism 
by which nicotine may prevent stress-induced impairment of 
memory and LTP. Moreover, the observation that stress-
induced atrophy of hippocampal neurons reversibly impairs 
cognitive function, suggests that chronic nicotine treatment 
may reduce the negative impact of excitotoxic amino acids 
and corticosteroids, and subsequently, prevent permanent 
damage and cognitive decline.  
  The combined effects of psychosocial stress and nicotine 
in AD have not been studied thoroughly in any AD animal 
model; hence this review summarizes recent findings that are 
largely reported from this laboratory. 
2. THE A RAT MODEL OF AD 
  A number of neuropathological features of AD have been 
reproduced in mice by the introduction of APP, PS1, and PS2 
transgenes [47-51]. The majority of transgenic mice exhibit 
cognitive deficits, amyloid peptides accumulation, and 
synaptic dysfunction, without showing neurofibrillary tangle 
formation, neuronal death, or microglial activation [52-55]. 
The establishment of double or triple-transgenic mice has 
improved the phenotypic similarities between animals and 
humans [56,57]. However, certain major limitations of 
transgenic mouse models of AD have been recognized. For 
example, the cerebrospinal fluid of these AD models contains 
a constant, high concentration of various A peptides, thus 
complicating investigation of the molecular bases of synaptic 
dysfunction. Additionally, the lack of neuronal death 
suggests that compensatory factors may be triggered by the 
introduction of transgenes into these mice [58]. 
  As a complementary alternative to transgenic animal 
models, non-transgenic models of AD are valuable tools for 
studying the specific pathogenesis induced by A. Similar to 
transgenic models, exogenous A administration does not 
reproduce the full complexity of the human AD pathology. 
However, studies involving exogenous administration of A 
have reported neurodegeneration and microglial activation, 
proximal to A deposits [50, 60]. Exogenous A administra- 
tion model of AD is not without limitations. For example, 
injection/infusion of A peptides is an invasive procedure, 
particularly when using osmotic pumps. The injury at the site 
of infusion may contribute to the induction of inflammatory 
processes. However, these limitations can be overcome to a 
significant degree by adjusting the infusion rate, the vehicle, 
the volume of injection, and the recovery time. 
  During normal cellular metabolism, neurons secrete   
low levels of soluble A peptides into cerebrospinal fluid 
and plasma [61, 62]. These peptides and their precursor,   
APP may have a physiological role in synaptic structure   
and function [63]. It has been suggested that the extent and 
rate at which the pool of soluble A oligomers accumulates 
is dependent on the rates of A catabolism and clearance 
[62, 64-66]. The A rat model was established by continuous 
osmotic pump infusion of a mixture of A1-40 and A1-42(300 
pmol/day) for 14 days. Control rats were similarly infused 
with the non-toxic reverse peptideA42-1 [18-21]. 
3. CHRONIC STRESS INTENSIFIES COGNITIVE 
DEFICITS  
  The radial arm water maze (RAWM) is a hybrid of the 
radial arm maze and the Morris water maze; it combines the 
variable spatial complexity of the radial arm maze with the 
rapid motivated learning of the Morris water maze while 
minimizing their disadvantages. It is a reliable and sensitive 
behavioral test for analyzing hippocampus dependent 
learning and memory [67-69]. 
  Seven experimental groups were designated as control, 
stress, nicotine, A, nicotine/A, stress/A and nicotine/ 
stress/A. The stress and stress/A groups were subjected to 
daily stress for 6 weeks and the A and A/stress groups 
were infused with a mixture of A1-40 and A1-42  (300 
pmol/day) during the fifth and sixth week. The control and 
stress groups were infused with A42-1, an inactive reverse 
peptide. The RAWM training protocol consisted of a 
learning phase of four 1-min consecutive learning trials- 
followed by a short-term and a long-term memory tests, 20 
min and 24 hr, respectively, after the last learning trial. The 
animals had to locate a black platform submerged 1 cm 
below the water level near the end of one of the 6 swim 
arms, This procedure was conducted for a minimum of 8 
consecutive days or until the rat satisfied a condition called 
days to criterion (DTC), which is defined as the number of 
days in which the rat commits a maximum of one error in 
three consecutive days in the fourth learning trial and 
memory tests [18-21, 70, 71]. 
  Days 6-8 of testing in the radial arm water maze clearly 
showed the significantly impaired ability of the stress/A rat 
group to learn compared to all other groups including the A 
group. For example, in trial 4, stress/A rats made 
significantly more errors in locating the hidden platform than 
the other rat groups including A rats. Furthermore, the A 
group made significantly more errors than the control and 
stress rat groups [18-20]. Chronic nicotine treatment (1 mg/ 
kg/12 hr) completely prevented the effect of A and the 
combination of A and stress [20]. Neither chronic stress 
alone nor nicotine alone had a significant effect on learning, 
which is in agreement with our previous findings [72].   
The effects on the learning curve were confirmed in the DTC 
test. In the learning phase, the stress/A rats required 
approximately twice the number of days as did the control and 
stress groups to reach the criterion for learning. Fig. (1A) [20].  
  Short-term memory was significantly impaired in both 
the stress and A groups. However, the stress/A group 
showed significantly greater impairment of short-term 
memory than all other groups. These results were further 
confirmed by the DTC test for short-term memory, which 
showed that although the A and stress groups required 
significantly more days to reach the criterion than control, 
the stress/A group required significantly more days than 
these two groups Fig. (1B) [18]. The deficits in stress,   
A and stress/A groups were prevented in all nicotine-
treated groups (nicotine/stress, nicotine/A and nicotine/ 
stress/A groups [18, 19]). Chronic Stress and Alzheimer’s Disease  Current Neuropharmacology, 2011, Vol. 9, No. 4    589 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Days to criterion (DTC) values; criterion is reached when a 
rat makes a maximum of one error per three consecutive days of 
testing in the RAWM. Chronic nicotine treatment prevents stress-
exacerbated impairment of learning, short-term, and long-term 
memory in A rats. (A) Memory function, measured as reaching 
DTC, indicated that the combination of stress and A impaired 
learning more than stress or A, alone, thus requiring stress/A rats 
to be trained for a minimum of 17 days in the RAWM in order to 
reach criterion. Neither nicotine, nor stress, alone, affects 
acquisition or long-term memory performance (C). Chronic 
nicotine treatment significantly prevents stress exacerbated A-
impairment of short-term (B) and long-term memory (C). All 
values are mean + S.E.M. (n=12-15 rats/group); *p<0.05 compared 
to control and nicotine-treated groups; **p<0.05 compared to all 
groups. Modified from references [18, 20]. 
  The 6-week psychosocial stress paradigm impairs short-
term memory but does not impair learning or long-term 
memory in normal rats [18, 73]. However, infusion of A in 
chronically stressed rats (stress/A group) caused a severe 
impairment of long-term memory [20] that was significantly 
greater than that caused by A infusion alone Fig. (1C). 
Again, nicotine prevented the effects of A and stress/A on 
long-term memory Fig. (1C) [20]. 
4. CHRONIC STRESS EXACERBATES IMPAIRMENT 
OF SYNAPTIC PLASTICITY IN AD MODEL 
  To relate cognitive deficit to possible changes in the 
cellular substrate of memory, we evaluated synaptic 
plasticity in area CA1 of the hippocampus. We recorded 
population spikes (pSpike) from area CA1 of anesthetized 
rats and determined changes in the slope of field excitatory 
postsynaptic potential (fEPSP: a measure of synaptic 
strength) and pSpike amplitude (a measure of the number of 
neurons firing action potentials) [72]. In these electro- 
physiological experiments, we first assessed basal synaptic 
function by applying a range of stimulus intensities to 
generate input-output (I/O) curves for all seven groups   
of animals. The I/O curves of A and stress/A groups 
showed a significant rightward shift compared with those of 
control and stress groups indicating impaired basal synaptic 
transmission in animals infused with A [18]. Chronic 
treatment with nicotine prevented impairment of basal 
synaptic transmission in these groups [18]. 
4.1. Early Phase Long-Term Potentiation (E-LTP) 
  E-LTP is believed to be a cellular correlate of short-term 
memory [74]. High frequency stimulation (HFS) in control 
rats induced a robust E-LTP, which lasted up to 3 hrs after 
HFS. However, in the stress, A and stress/A animals,   
the maximum increase in the response 5 min after HFS,   
was only about 50% of that of the control animals Fig. (2A) 
[18]. The E-LTP magnitude, measured as fEPSP or pSpike 
amplitude, in these 3 groups gradually decayed such that, at 
60 min post-HFS the fEPSP slope of the stress/A group was 
not different from that of the base line, thus, was 
significantly lower than those of the other groups including 
the stress and the A groups [18, 19]. In the nicotine treated 
A and stress/A rats, E-LTP was not significantly different 
than those of the control or nicotine alone groups Fig. (2A). 
4.2. Late Phase LTP (L-LTP) 
  L-LTP, evoked by multiple-train HFS, was so severely 
impaired in the stress/A rats that at 5 hr after HFS, the slope 
of fEPSP was significantly lower than the baseline Fig. (2B) 
[21]. The magnitude of L-LTP of animals of the A group 
was significantly lower than that of control group. The 
magnitude of L-LTP of the three nicotine treated rat groups 
(nicotine, nicotine/stress/A and nicotine/A) was not 
significantly different than that of the control group. Thus, 
nicotine prevented the A-induced impairment of synaptic 
plasticity. It is interesting to note that although stress 
markedly accentuates the effect of A infusion, it has no 
significant effect on L-LTP in normal animals [7] as we have 
reported earlier Fig. (2B) [11, 21, 73, 75]. 
A
B
C
*
*
* *
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4.3. Long-Term Depression (LTD) 
  Just as high levels of synaptic activity potentiate synaptic 
transmission, low levels of persistent stimulation depress 
hippocampal synapses. Thus, to examine the mechanism 
responsible for stress and/or A-mediated impairment of 
LTP, we examined the magnitude of n-methyl-d-aspartate 
(NMDA)-dependent LTD expressed in the Schaffer collaterals 
pathway using paired pulse protocol in anesthetized animals 
[21, 72, 75]. All animal groups displayed robust LTD, which 
was measured as decreases in the slope of fEPSP. Chronic 
stress or A- infusion, alone, caused a significantly greater 
reduction in synaptic strength than that seen in control 
animals. The magnitude of LTD in stress/A animals   
was significantly greater than that in control, stress, and   
A animals. Chronic nicotine administration prevented the 
effect of stress and/or A on LTD and restored the synaptic 
signal to a magnitude comparable to that of control animals 
[21].  
5. CHRONIC STRESS ACCENTUATES ALTERED 
LEVELS OF SIGNALING MOLECULES ESSENTIAL 
FOR MEMORY AND SYNAPTIC PLASTICITY 
  Calcium calmodulin kinase II (CaMKII) plays a critically 
important role in the memory and LTP processes. Under 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Hippocampal long-term potentiation (LTP) of the CA1 region evoked by repetitive stimulation (applied at t=0) of the Schaffer 
collaterals/commissural pathway and measured as increases in the slope of fEPSP in urethane-anesthetized rats. (A) Early phase (E-LTP), 
evoked by high frequency stimulation (HFS), was significantly decreased in stress and/or A groups. Chronic nicotine treatment significantly 
prevented stress-induced E-LTP suppression in A rats. (B) Late-phase (L-LTP), evoked by multiple high frequency stimulation (MHFS), 
was significantly decreased in the A and stress/A groups. Chronic nicotine treatment prevented the effects of both stress and/or A. Values 
are mean + S.E.M. from 5-8 rats (*p<0.05 compared to control animals; #p<0.05 compared to all animals). Insets are traces from 
representative experiments. Modified from references [18, 19]. 
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normal conditions, induction of LTP by HFS leads to a 
persistent increase in the levels and activity of phos- 
phorylated (p)-CaMKII and calcineurin in hippocampal 
slices [76] and anesthetized animal hippocampi [9, 11, 18]. 
Activation of NMDA receptor causes a transient increases in 
intracellular calcium concentrations leading to autophos- 
phorylation of CaMKII [77]. The rapid autophosphorylation 
of CaMKII results in a constitutively active CaMKII [78] 
that phosphorylates and activates -amino-3-hydroxy-5-
methyl-4-isoxazole (AMPA) receptors and the synaptic 
vesicle-specific protein, synapsin, which are important for 
LTP expression [76,79,80]. It is proposed that activation of 
CaMKII serves as a molecular switch that converts transient 
Ca
2+  signals into long lasting biochemical changes that 
trigger synaptic plasticity [81]. 
  To further elucidate the potential mechanism by which 
stress exacerbated A-induced impairment of cognitive 
abilities and synaptic plasticity, we evaluated the effect of 
chronic stress and A on the basal levels of signaling 
molecules essential for these processes by immunoblot 
analysis. Table 1 summarizes the results of these experiments.  
5.1. Basal Levels of CaMKII and Calcineurin 
  Although chronic stress or A markedly reduced the   
basal levels of phosphorylated CaMKII, these levels were 
significantly more reduced in the CA1 of stress/A animals 
Fig. (3A) [18]. In normal animals, nicotine did not change 
the basal levels of this enzyme, but it completely prevented 
the effect of stress, A or stress/A on the levels of CaMKII 
Fig. (3A) [20]. 
  Phosphorylated CaMKII is normally dephosphorylated 
by a protein phosphatase, principally calcineurin, which is  
a negative modulator of cognitive memory and seems to   
be involved in AD pathogenesis. For example, inhibiting   
calcineurin with tacrolimus (FK506) reversed cognitive   
impairment in Tg2576 mice [82]. Immunoblot analysis   
revealed significant increase in the basal levels of calcineurin 
in the stress, A and stress/A groups compared to those   
of the control group Fig (3B) [18, 21] and that nicotine   
treatment normalized calcineurin levels in these animals   
Fig. (3B) [21].  
5.2. Basal Levels of CREB and CaMKIV 
  cAMP response element-binding protein (CREB) signaling, 
a necessary component for hippocampus-dependent long-
term memory formation in mammals [83, 84], is severely 
compromised by A [85]. We measured basal levels of 
phosphorylated and total (phosphorylated and non-
phosphorylated) CREB. Although the basal levels of p-
CREB were significantly reduced in the A and stress/A 
groups, the levels of total CREB were unchanged in these 
groups [20]. The ratio of basal protein levels of p-CREB to t-
CREB was significantly (p<0.05) decreased in A rats, and 
stress/A rats, compared to control rats Fig. (4A) [20]. The 
decreases in the ratio of p-CREB:t-CREB correlated with 
reduced phosphorylation of CREB. Furthermore, that the 
ratio of p-CREB to t-CREB was significantly higher in 
nicotine/Aand nicotine/stress/A rats compared to A and 
stress/A rats, but not significantly different from control 
rats, suggested that chronic nicotine treatment prevented A- 
and stress/A-induced inhibition of CREB phosphorylation 
[20].  
  During expression of L-LTP, there is an increase in the 
basal levels of CaMKIV, which directly phosphorylates 
CREB [86]. We reported that basal levels of CaMKIV were 
significantly reduced in A animals and stress/A animals, 
compared to control animals [20]. By contrast, six weeks of 
chronic nicotine treatment normalized the basal levels of 
CaMKIV in these two groups. The basal levels of CaMKIV 
in nicotine, stress, nicotine/A, and nicotine/stress/A  
animals were not significantly different from control animals 
[20]. 
5.3. Basal Levels of Brain Derived Neurotropic Factor 
(BDNF) 
  The levels of neurotrophic factors, including BDNF, are 
increased in specific brain regions in response to various 
types of insults, including ischemia, seizure, traumatic brain 
injury, and neurotoxins [87]. A possible role for nicotine-
mediated neuroprotection has been suggested by studies 
showing that nicotinic receptor activation increases the levels 
of neurotrophic factors, including BDNF [88]. Since BDNF 
plays a major role in neuronal survival [89], we examined 
Table 1.  Summary of the Effects of Nicotine and/or Stress on the Basal Levels of Essential Signalling Molecules in CA1 Area of the 
Hippocampus in A-Treated Rats Compared to Control. Decreased,  Increased,  No Change 
 Nicotine  Stress  A Nic/A Str/A Nic/Str/A 
p-CaMKII             
t-CaMKII             
Calcineurin             
BDNF             
p-CREB             
t-CREB             
CaMKIV             592    Current Neuropharmacology, 2011, Vol. 9, No. 4  Karim A. Alkadhi 
the protein expression of BDNF in the seven groups of rats. 
Immunoblot analyses revealed significantly (p<0.05) higher 
levels of BDNF in A and stress/A rats, compared to 
control rats Fig. (4B) [20]. The increased basal protein levels 
of BDNF in area CA1 of A-infused rats is in agreement 
with an earlier report that shows an increase in the protein 
levels of BDNF in the forebrain in APPsw mice [90]. 
  That we have detected an increased level of BDNF 
protein in an area heavily susceptible to A toxic effects is in 
line with the role of BDNF in the maintenance and repair of 
neurons [91] and suggests that in early AD, a compensatory 
mechanism is activated to protect neurons from A-induced 
neurotoxicity. Furthermore, as chronic nicotine treatment   
is known to upregulate BDNF protein level and mRNA 
expression in area CA1 [9, 90], it is not surprising that 
BDNF protein levels are significantly increased in nicotine, 
nicotine/A, and nicotine/stress/A rats, compared to control 
rats Fig. (4B). This finding is in agreement with earlier reports 
showing that chronic nicotine treatment increased BDNF 
protein levels in APPsw mice [90] and normal rats [9].  
  We have shown that BDNF levels in stress/A rats are 
not significantly different from nicotine/stress/A rats [20]. 
The lack of a significant difference may be due to maximal 
expression of BDNF in the presence of a chronic disease 
state. For example, in post-mortem AD brains, BDNF levels 
have been shown to be significantly higher in the parietal 
cortex and hippocampus, compared to controls [87]. It is 
worth mentioning that Hock and colleagues [92] reported a 
2-fold decrease in mRNA levels of BDNF in AD 
postmortem parietal cortex. This suggests that, perhaps, in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). (A) Ratio of basal levels of phosphorylated-calcium-calmodulin-dependent protein kinase II (p-CaMKII) to total (t)-CaMKII in 
CA1. Values are mean + S.E.M. from 5-7 rats/group (*p<0.05 compared to control and nicotine-treated animals; #p<0.05 compared to all 
groups). (B) Basal levels of calcineurin in area CA1. Nicotine prevents the adverse effect of chronic stress on A-induced increases in basal 
calcineurin levels in hippocampal homogenates. Values are mean + S.E.M. from 5-7 rats (*p<0.05 compared to control and nicotine-treated 
animals (nicotine, nicotine/A, nicotine/stress/A). Insets: representative immunoblot images. Modified from references [18, 19]. 
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early stages of AD, BDNF protein levels are increased to 
bring about protection of neuron from the onslaught of the 
pathogenic peptides and that at later AD stages, BDNF 
protein levels are decreased. Together, the data suggest that 
BDNF is involved in the regulation of nicotine-mediated 
neuroprotection in A and stress/A rats [20]. 
6. POSSIBLE MECHANISMS OF THE EFFECTS OF 
STRESS 
  Previously, we have shown that chronic stress decreases 
basal levels of p-CaMKII in the CA1 region, and 
subsequently reduces the magnitude of HFS-induced LTP 
[11, 19]. Furthermore, the presence of abnormal levels of A 
peptides disrupts phosphorylation of CaMKII and interferes 
with LTP induction, as reported in both in vivo and in vitro 
studies [19, 93, 94]. Based on findings from our model,   
we propose that decreasing CaMKII-dependent protein   
phosphorylation may contribute to the mechanism by   
which chronic stress impairs memory and LTP in this model 
of AD.  
  In general, activation of mineralocorticoid (type-I) 
receptor by low levels of corticosteroids produces Ca
2+ 
influx, which has an excitatory effect on hippocampal CA1 
pyramidal cells, whereas activation of glucocorticoid (type-
II) receptor by high levels of corticosteroids during stressful 
conditions greatly enhances Ca
2+  influx and inhibits CA1 
pyramidal cell excitability [35, 95]. Given the stress-induced 
glucocorticoid effects on Ca
2+ dynamics, it is not surprising 
that stress worsens Ca
2+-dependent signaling processes in A 
rats. This finding is in line with previous reports suggesting 
that A perturbs intracellular Ca
2+ signaling [26, 96, 97]   
and inhibits Ca
2+-dependent post-translational protein 
phosphorylation [64]. For example, studies by Zhao et al. 
[94] using acute application of A1-42 during HFS showed 
inhibition of LTP in the dentate gyrus, with corresponding 
reductions in p-CaMKII levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). (A) Ratio of basal levels of phosphorylated-cyclic AMP response element binding (p-CREB) to total (t)-CREB in area CA1.  
Values are mean + S.E.M. from 5-7 rats/group (*p<0.05 compared to control and nicotine-treated animals). (B) Basal levels of brain- 
derived neurotrophic factor (BDNF) in area CA1. Animals were treated with (-) nicotine or saline for 6 weeks. Groups treated with nicotine 
showed increased levels of BDNF (Values are mean + S.E.M.; n=5-7 rats/group; *p<0.01 compared to control animals. Modified from 
reference [20]. 
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  Brain-derived neurotrophic factor plays a major role in 
neuronal survival [89, 91]. The levels of neurotrophic 
factors, including BDNF, are increased in specific brain 
regions in response to various types of insults, including 
ischemia, seizure, traumatic brain injury, and neurotoxins 
[87, 98]. Earlier reports that show an increase in the protein 
levels of BDNF in the forebrain in APPsw mice [90] and 
area CA1 in A-treated rats [19], suggest that in early AD,  
a protective mechanism may be activated to counter the   
A-induced neurotoxicity. In contrast, chronic stress has 
been reported to significantly decrease BDNF levels in   
area CA1 of the hippocampus [9]. Therefore, by limiting the 
availability of BDNF, stress interferes with the repair process 
and consequently exacerbating the effect of A.  
  Interestingly, recent reports have shown that the 
expression of nerve cell adhesion molecule (NCAM) is 
increased in the brains of AD patients [99] suggesting 
probable neurogenesis [100]. This could be an attempt by the 
brain to repair or replace neurons lost to the disease. In 
contrast to AD, chronic stress is known to cause severe 
reduction in NCAM levels [100, 101]. We speculate that the 
neurotoxic effect of A in the brain might be initially offset 
through repair as suggested by the reported increased levels 
of NCAM. However, in the presence of chronic stress, the 
ability of NCAM to repair is severely limited by the stress-
induced reduction in the concentration of these protein 
molecules. 
  Another possible mechanism for the stress effect is that 
stress may alter the processing and production of various 
AD-related proteins. It has been shown that exposure to 
stress or glucocorticoids increases the levels of APP, C99, 
and BACE, suggesting that stress is driving the processing of 
APP toward the amyloidogenic pathway which may account 
for the increased levels of A [18, 19, 102] and the increased 
amount of plaque formation [103] that are also observed with 
stress. 
7. POSSIBLE MECHANISM OF THE NEURO- 
PROTECTIVE EFFECTS OF NICOTINE 
  Our finding that nicotine reduces amyloid levels [19] is 
in accordance with reports that nicotine and its metabolites 
(cotinine) inhibit -amyloidosis [104-106]. Based on the 
original “binding surface hypothesis” of Hilbich et al. [107] 
the authors suggest that nicotine and cotinine delay or inhibit 
-amyloidosis by non-specifically binding to A and 
preventing an -helix to -sheet conformational conversion 
[104-106]. It is postulated that nicotine binds to histidine 
residues (His6 and His13) on the -helix [104], or to small, 
soluble -sheet aggregates [106], and increases the average 
separation between A monomers in solution, thus delaying 
the onset of aggregation [106, 108]. Similarly, studies using 
nornicotine, another nicotine metabolite, demonstrate that 
nornicotine-based covalent glycation of lysine-16 on the A 
peptide, occludes the A polymerization domain, and thus, 
delays formation of the oligomeric -sheet structure [105].  
It is unclear whether nicotine-mediated inhibition of   
A deposition, aggregation, and/or -amyloidosis is due   
to altered processing (towards a non-amyloidogenic A 
sequence), decreased synthesis, or increased clearance of A 
peptides. However, a recent study found that chronic 
nicotine treatment (1 mg/kg/day and 8 mg/kg/day) reduced 
rat CSF levels of APP, which contains the amyloidogenic 
A fragment, without significantly altering total soluble APP 
levels [109, 110]. This suggests that nicotine exerts its 
effects, in part, by altering the processing of APP away from 
an amyloidogenic route, towards increased production of 
APP-carboxyl-terminally truncated forms, which do not 
contain A1-40 and/or A1-42. Furthermore, whereas no single 
mechanism for nicotine-mediated protection has been 
determined, studies have shown that nicotine increases the 
levels of neuronal growth factors including BDNF [9, 111, 
112], decreases the levels of nitric oxide generated in 
response to neuronal injury [113], and inhibits glutamate-
evoked arachidonic acid release from cultured striatal 
neurons [114].  
  Another possible mechanism by which nicotine 
attenuates the AD-like symptoms is by opposing inflamma- 
tory effect of the disease. Inflammatory response is one of 
the first immune processes in injury. It involves the 
production of specific molecules that set off the migration of 
immune cells to wherever the lesion site is, including in the 
brain. Thus, in stroke, as well as during chronic illnesses, 
including AD, inflammation takes place in order to clear out 
and isolate the lesion area. However, sustained inflammation 
can cause neurotoxicity, which exacerbates the severity of 
the disease. It is well known that cholinergic anti-inflamma- 
tory cascade regulates inflammatory cytokine production 
through the vagus nerve-dependent pathway involving   
7-nicotinic acetylcholine receptor (7nAChR). Activation 
of this pathway decreases tumor necrosis factor (TNF)  
and blood interleukin-1 levels, inhibits TNF production   
and reduces pro-inflammatory gene expression. Initiation   
of this pathway through vagus nerve stimulation or directly 
by treatment with nicotinic receptor agonists, including 
nicotine, activates macrophagal 7nAChRs, resulting in   
anti-inflammatory effects [115-118]. Thus, the 7nAChR-
mediated anti-inflammatory action may also contribute to the 
anti-AD effects of nicotine.  
8. SUMMARY  
  In summary, the presence of chronic stress accentuates 
the severity of phenotypes in AD rat model. This impairment 
is likely associated with a number of inter-related 
disturbances of various signaling molecule pathways 
including failure of phosphorylated CaMKII to increase after 
the induction of LTP. The results of these studies suggest 
that in addition to the onslaught of A-associated cognitive 
insults wrought on the AD brain, the coincidence of chronic 
stress further compromises mental abilities in AD patients 
and accelerates the progression of the disease. 
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